45 related articles for article (PubMed ID: 17038352)
1. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans.
Mizushima T; Yagi H; Takemoto E; Shibata-Koyama M; Isoda Y; Iida S; Masuda K; Satoh M; Kato K
Genes Cells; 2011 Nov; 16(11):1071-80. PubMed ID: 22023369
[TBL] [Abstract][Full Text] [Related]
2. Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG.
Matsumoto Y; Jia N; Heimburg-Molinaro J; Cummings RD
Sci Rep; 2023 Mar; 13(1):5027. PubMed ID: 36977722
[TBL] [Abstract][Full Text] [Related]
3. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
Pereira NA; Chan KF; Lin PC; Song Z
MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Parkinson's disease with biologics that penetrate the blood-brain barrier via receptor-mediated transport.
Pardridge WM
Front Aging Neurosci; 2023; 15():1276376. PubMed ID: 38035276
[TBL] [Abstract][Full Text] [Related]
5. Engineering protein-based therapeutics through structural and chemical design.
Ebrahimi SB; Samanta D
Nat Commun; 2023 Apr; 14(1):2411. PubMed ID: 37105998
[TBL] [Abstract][Full Text] [Related]
6. A Historical Review of Brain Drug Delivery.
Pardridge WM
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745855
[TBL] [Abstract][Full Text] [Related]
7. Profiling of N-Linked Oligosaccharides of a Glycoprotein by UPLC-FLR-ESI-MS After Derivatization with Fluorescent Anthranilamide.
Butré CI; Largy E; Delobel A
Methods Mol Biol; 2021; 2271():179-188. PubMed ID: 33908008
[TBL] [Abstract][Full Text] [Related]
8. Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.
Kim JE; Lee DH; Jung K; Kim EJ; Choi Y; Park HS; Kim YS
Front Immunol; 2020; 11():593748. PubMed ID: 33488590
[TBL] [Abstract][Full Text] [Related]
9. A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis.
Mahan AE; Tedesco J; Dionne K; Baruah K; Cheng HD; De Jager PL; Barouch DH; Suscovich T; Ackerman M; Crispin M; Alter G
J Immunol Methods; 2015 Feb; 417():34-44. PubMed ID: 25523925
[TBL] [Abstract][Full Text] [Related]
10. Fc-fusion proteins: new developments and future perspectives.
Czajkowsky DM; Hu J; Shao Z; Pleass RJ
EMBO Mol Med; 2012 Oct; 4(10):1015-28. PubMed ID: 22837174
[TBL] [Abstract][Full Text] [Related]
11. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.
Chung S; Quarmby V; Gao X; Ying Y; Lin L; Reed C; Fong C; Lau W; Qiu ZJ; Shen A; Vanderlaan M; Song A
MAbs; 2012; 4(3):326-40. PubMed ID: 22531441
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.
Zhou QH; Sumbria R; Hui EK; Lu JZ; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 2011 Nov; 339(2):618-23. PubMed ID: 21831964
[TBL] [Abstract][Full Text] [Related]
13. Production of therapeutic antibodies with controlled fucosylation.
Yamane-Ohnuki N; Satoh M
MAbs; 2009; 1(3):230-6. PubMed ID: 20065644
[TBL] [Abstract][Full Text] [Related]
14. Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC.
Natsume A; Niwa R; Satoh M
Drug Des Devel Ther; 2009 Sep; 3():7-16. PubMed ID: 19920917
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides.
Shoji-Hosaka E; Kobayashi Y; Wakitani M; Uchida K; Niwa R; Nakamura K; Shitara K
J Biochem; 2006 Dec; 140(6):777-83. PubMed ID: 17038352
[TBL] [Abstract][Full Text] [Related]
16. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Immunol Methods; 2005 Nov; 306(1-2):93-103. PubMed ID: 16236307
[TBL] [Abstract][Full Text] [Related]
17. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
Niwa R; Natsume A; Uehara A; Wakitani M; Iida S; Uchida K; Satoh M; Shitara K
J Immunol Methods; 2005 Nov; 306(1-2):151-60. PubMed ID: 16219319
[TBL] [Abstract][Full Text] [Related]
18. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
[TBL] [Abstract][Full Text] [Related]
19. [Potelligent antibodies as next generation therapeutic antibodies].
Shitara K
Yakugaku Zasshi; 2009 Jan; 129(1):3-9. PubMed ID: 19122430
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
